Participation in another clinical study in the previous month

Severe concomitant disease which may have an impact on the study participation

Hypersensitivity against Ectoin

Myocardial infarction or apoplexy within the last year

Uncontrolled hypertension: systolic blood pressure \>200 mmHg or diastolic pressure \>120 mmHg

Known aortic aneurysm

Other respiratory diseases (e.g. cystic fibrosis, alpha-1-Antitrypsin deficiency, sarcoidosis, allergic alveolitis, tuberculosis, etc.)

Patients who have had treatment with live attenuated vaccinations within 14 days prior to screening visit (Inactivated influenza vaccination is acceptable, provided it is not administered within 7 days prior to screening visit)

on investigators decision

Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung

What this study is about